MMAD

Research use only, not for human use.

MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs).

MMAD, also known as Monomethyl auristatin D, is a highly potent tubulin inhibitor. MMAD is one of the auristatins, which are used as antibody drug conjugates (ADCs).

MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity.

The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats.

MMAD, Demethyldolastatin 10 | Monomethyl Dolastatin 10

Endocrinology/Hormones

5-HT Receptor

Microtubule/Tubulin

Cancer

——

203849-91-6

771.06

C41H66N6O6S

>98% (HPLC)

DMSO : 24.5 mg/mL 31.77 mM

O=C(N[C@@H](Cc1ccccc1)c2nccs2)[C@H](C)[C@@H](OC)[C@@H]3CCCN3C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C

(S)-N-((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide

(-20℃)

With Ice Pack

≥ 2 years